Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for macular edema due to central retinal vein occlusion
2009-017782-30Phase 3Completed
- Sponsor
- Department of Ophthalmology, Medical University of Graz
- Start
- Feb 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in macular edema and central retinal vein occlusion (CRVO), sponsored by Department of Ophthalmology, Medical University of Graz. Primary endpoint: Change in visual acuity at 12 months. Started Feb 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
macular edemacentral retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on 2009-017782-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017782-30.